ArticleCancer2023

Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.

Meghan J Mooradian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.